Pharmacoeconomic review report. Mifepristone and misoprostol (Mifegymiso).
Mifepristone and misoprostol (Mifegymiso) is a combination drug product comprising a progesterone receptor antagonist and a synthetic analogue of prostaglandin E1. It is approved by Health Canada for the medical termination of a developing intrauterine pregnancy with a gestational age up to 49 days....
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK534601/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2017
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
